Assimilating the Evidence in T2DM
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Cannon CP, McGuire DK, Pratley R, et al. Am Heart J. 2018;206:11-23.
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
DeFronzo RA, Norton L, Abdul-Ghani M. Nat Rev Nephrol. 2017;13(1):11-26.
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.
Kato ET, Silverman MG, Mosenzon O, et al. Circulation. 2019;139(22):2528‐2536.
Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.
King RJ, Grant PJ. Herz. 2016;41(3):184-192.
Diabetes mellitus and heart failure.
Lehrke M, Marx N. Am J Cardiol. 2017; 120(suppl 1):S37-S47.
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
Maack C, Lehrke M, Backs J, et al. Eur Heart J. 2018;39(48):4243‐4254.
Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.
Mahaffey KW, Jardine MJ, Bompoint S, et al. Circulation. 2019;140(9):739-750.
Dapagliflozin in patients with heart failure and reduced ejection fraction.
McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med. 2019;381(21):1995-2008.
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med.2017;377(7):644-657.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019;380(24):2295-2306.
Timing of onset of clinical benefit with dapagliflozin in patients with heart failure: an analysis from the dapagliflozin and prevention of adverse-outcomes in heart failure trial (DAPA-HF).
Sabatine MS, DeMets DL, Inzucchi SE, et al. Circulation. 2019;140(25):e973.
Diabetic kidney disease.
Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.
SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome.
van Bommel EJ, Muskiet MH, Tonneijck L, et al. Clin J Am Soc Nephrol. 2017;12(4):700-710.
Empagliflozin and progression of kidney disease in type 2 diabetes.
Wanner C, Inzucchi SE, Lachin JM, et al. N Engl J Med. 2016;375(4):323-334.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393(10166):31-39.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.
Clinical Practice Guidelines
Standards of medical care in diabetes—2020.
American Diabetes Association. Diabetes Care. 2020;43(suppl 1):S1-S212.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary.
Garber AJ, Handelsman Y, Grunberger G, et al. Endocr Pract. 2020;26(1):107‐139.
Patient and Caregiver Resources
American Association of Diabetes Educators
American Diabetes Association
Centers for Disease Control and Prevention: Diabetes Education and Support
National Diabetes Education Program
Assimilating the Evidence in T2DM
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
| Faculty: | Daniel Einhorn, MD, FACE, FACP; Serge A. Jabbour, MD, FACP, FACE; Marc S. Sabatine, MD, MPH; Kumar Sharma, MD |
| Release: | 08/17/2020 |
| Expiration: | 08/17/2021 |
